Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 44.24
BTX's Cash to Debt is ranked higher than
51% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. BTX: 44.24 )
Ranked among companies with meaningful Cash to Debt only.
BTX' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 10000.00 Max: No Debt
Current: 44.24
Equity to Asset 0.17
BTX's Equity to Asset is ranked lower than
89% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BTX: 0.17 )
Ranked among companies with meaningful Equity to Asset only.
BTX' s Equity to Asset Range Over the Past 10 Years
Min: -45.87  Med: 0.33 Max: 0.99
Current: 0.17
-45.87
0.99
F-Score: 4
Z-Score: -3.86
M-Score: -1.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -784.55
BTX's Operating margin (%) is ranked lower than
75% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. BTX: -784.55 )
Ranked among companies with meaningful Operating margin (%) only.
BTX' s Operating margin (%) Range Over the Past 10 Years
Min: -1262.63  Med: -244.59 Max: -116.83
Current: -784.55
-1262.63
-116.83
Net-margin (%) -590.96
BTX's Net-margin (%) is ranked lower than
74% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. BTX: -590.96 )
Ranked among companies with meaningful Net-margin (%) only.
BTX' s Net-margin (%) Range Over the Past 10 Years
Min: -989.69  Med: -284.44 Max: -137.48
Current: -590.96
-989.69
-137.48
ROE (%) -214.71
BTX's ROE (%) is ranked lower than
93% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. BTX: -214.71 )
Ranked among companies with meaningful ROE (%) only.
BTX' s ROE (%) Range Over the Past 10 Years
Min: -2802.7  Med: -142.41 Max: -49.44
Current: -214.71
-2802.7
-49.44
ROA (%) -61.77
BTX's ROA (%) is ranked lower than
76% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. BTX: -61.77 )
Ranked among companies with meaningful ROA (%) only.
BTX' s ROA (%) Range Over the Past 10 Years
Min: -624.96  Med: -85.72 Max: -33.33
Current: -61.77
-624.96
-33.33
ROC (Joel Greenblatt) (%) -1398.68
BTX's ROC (Joel Greenblatt) (%) is ranked lower than
65% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. BTX: -1398.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BTX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -21242.11  Med: -2773.13 Max: -1730.98
Current: -1398.68
-21242.11
-1730.98
Revenue Growth (3Y)(%) -3.90
BTX's Revenue Growth (3Y)(%) is ranked lower than
56% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. BTX: -3.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BTX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 7.00 Max: 115.4
Current: -3.9
0
115.4
EBITDA Growth (3Y)(%) 22.30
BTX's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. BTX: 22.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BTX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.9  Med: 8.90 Max: 63.9
Current: 22.3
-48.9
63.9
EPS Growth (3Y)(%) 16.10
BTX's EPS Growth (3Y)(%) is ranked higher than
74% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. BTX: 16.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BTX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -35.1  Med: 9.75 Max: 64
Current: 16.1
-35.1
64
» BTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

BTX Guru Trades in

Q2 2014

BTX Guru Trades in Q2 2014

Jim Simons Sold Out
» More
Q2 2015

BTX Guru Trades in Q2 2015

Jim Simons 165,000 sh (New)
» More
Q3 2015

BTX Guru Trades in Q3 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 13.71
BTX's P/B is ranked lower than
99.99% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. BTX: 13.71 )
Ranked among companies with meaningful P/B only.
BTX' s P/B Range Over the Past 10 Years
Min: 5.22  Med: 11.41 Max: 44.08
Current: 13.71
5.22
44.08
P/S 23.06
BTX's P/S is ranked lower than
72% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 9.13 vs. BTX: 23.06 )
Ranked among companies with meaningful P/S only.
BTX' s P/S Range Over the Past 10 Years
Min: 4.5  Med: 36.65 Max: 114.6
Current: 23.06
4.5
114.6
Current Ratio 3.32
BTX's Current Ratio is ranked lower than
59% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. BTX: 3.32 )
Ranked among companies with meaningful Current Ratio only.
BTX' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 4.03 Max: 76
Current: 3.32
0.02
76
Quick Ratio 3.30
BTX's Quick Ratio is ranked lower than
57% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. BTX: 3.30 )
Ranked among companies with meaningful Quick Ratio only.
BTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 4.00 Max: 74
Current: 3.3
0.02
74
Days Inventory 85.20
BTX's Days Inventory is ranked higher than
64% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 124.17 vs. BTX: 85.20 )
Ranked among companies with meaningful Days Inventory only.
BTX' s Days Inventory Range Over the Past 10 Years
Min: 44.57  Med: 97.03 Max: 540.98
Current: 85.2
44.57
540.98
Days Sales Outstanding 145.62
BTX's Days Sales Outstanding is ranked lower than
85% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 62.58 vs. BTX: 145.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
BTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 91.79  Med: 95.33 Max: 98.86
Current: 145.62
91.79
98.86
Days Payable 598.74
BTX's Days Payable is ranked higher than
97% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 57.61 vs. BTX: 598.74 )
Ranked among companies with meaningful Days Payable only.
BTX' s Days Payable Range Over the Past 10 Years
Min: 982.3  Med: 1291.37 Max: 5165.44
Current: 598.74
982.3
5165.44

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.60
BTX's Price/Median PS Value is ranked higher than
75% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BTX: 0.60 )
Ranked among companies with meaningful Price/Median PS Value only.
BTX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 1.26 Max: 14.27
Current: 0.6
0.13
14.27
Earnings Yield (Greenblatt) (%) -25.77
BTX's Earnings Yield (Greenblatt) (%) is ranked lower than
74% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. BTX: -25.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BTX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -25.77  Med: 0.00 Max: 0
Current: -25.77
-25.77
0

More Statistics

Revenue(Mil) $7
EPS $ -0.57
Beta1.47
Short Percentage of Float14.09%
52-Week Range $2.03 - 5.50
Shares Outstanding(Mil)94.89

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 6 7 7
EPS($) -0.61 -0.70 -0.54
EPS without NRI($) -0.61 -0.70 -0.54

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BT3.Germany, BTX.Israel,
BioTime Inc was incorporated in 1990 in the state of California. It is a biotechnology company engaged in two areas of biomedical research and product development. Its main focus is in the field of regenerative medicine; specifically human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. Its core technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. Products made from these pluripotent stem cells are being developed by the Company and its subsidiaries, for use in various fields of medicine, including: neuroscience, oncology, orthopedics, and blood and vascular diseases. HyStem, Hextend, ESpy, PureStem, and PentaLyte are registered trademarks of the Company and Renevia, Premvia, ReGlyde, and ESpan are trademarks of the Company.
» More Articles for BTX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BTX, CWST, BKSC, STAG Jun 27 2011 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 

More From Other Websites
BioTime, Inc. to Present at Three Investor Conferences in February Feb 01 2016
BioTime, Inc. to Present at Three Investor Conferences in February Feb 01 2016
BIOTIME INC Files SEC form 8-K, Entry into a Material Definitive Agreement Jan 27 2016
LifeMap Sciences, a Subsidiary of BioTime, Announces the Launch of TGex™, the Knowledge-Driven NGS... Jan 20 2016
Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018 Jan 12 2016
BIOTIME INC Files SEC form 8-K, Material Modification to Rights of Security Holders, Financial... Jan 12 2016
Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018 Jan 12 2016
BIOTIME INC Financials Jan 07 2016
BioTime, Inc. breached its 50 day moving average in a Bearish Manner : January 5, 2016 Jan 05 2016
OncoCyte Corporation Initiates Trading on the NYSE MKT Jan 04 2016
BioTime Completes Distribution of Approximately 4.75 Million Shares of OncoCyte Corporation Common... Dec 31 2015
BIOTIME INC Files SEC form 8-K, Other Events Dec 31 2015
BioTime Completes Distribution of Approximately 4.75 Million Shares of OncoCyte Corporation Common... Dec 31 2015
BIOTIME INC Files SEC form 8-K, Other Events Dec 30 2015
BioTime Announces “When-Issued” Trading of Subsidiary OncoCyte Corporation in Connection With... Dec 30 2015
BioTime Announces “When-Issued” Trading of Subsidiary OncoCyte Corporation in Connection With... Dec 30 2015
OncoCyte Appoints Dr. Andrew J. Last to Its Board of Directors Dec 23 2015
BioTime, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 22 2015
Coverage initiated on BioTime by Oppenheimer Dec 22 2015
Stephen C. Farrell Appointed to STAAR Surgical Board of Directors Dec 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK